WayPoint Biomedical Holdings, Inc. (WYPH) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
WayPoint Biomedical Holdings, Inc. (WYPH) trades at $0.0005 with AI Score 47/100 (Grade C). WayPoint Biomedical Holdings, Inc. operates in the diagnostic testing and homeland security sectors. Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for WYPH: WYPH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates WYPH against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
WYPH: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
WayPoint Biomedical Holdings, Inc. (WYPH) Financial Services Profile
WayPoint Biomedical Holdings, Inc. focuses on developing and marketing diagnostic tests and devices for human health, fitness, and security applications. Its product portfolio includes drink spiking detection and explosive residue tests, targeting over-the-counter, point-of-care, and homeland security markets, operating within the financial services sector as a shell company.
What Is the Investment Thesis for WYPH?
WayPoint Biomedical Holdings, Inc. presents a speculative investment opportunity given its focus on niche diagnostic testing and security solutions. The company's product portfolio, including the Drink Detective and explosive detection kits, targets specific market needs. However, the company's financial performance, indicated by a negative P/E ratio of -0.25 and a market capitalization of $0.00B, suggests significant challenges. The beta of -8.36 indicates high volatility. Growth catalysts depend on successful commercialization of its diagnostic tests and expansion into the homeland security market. Investors should carefully consider the risks associated with investing in a shell company operating in the OTC market.
Based on FMP financials and quantitative analysis
WYPH Key Highlights
Market Cap of $0.00B indicates a micro-cap company with limited resources.
- P/E Ratio of -0.25 suggests the company is not currently profitable.
- Beta of -8.36 indicates high volatility compared to the market.
- Operates in the OTC market, which typically involves higher risks and lower liquidity.
- Focus on niche markets such as drink spiking detection and explosive residue testing.
Who Are WYPH's Competitors?
WYPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NIHL New Infinity Holdings, Ltd. | $0.10 | +0.00% | $10.8M | 62 |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.4M | 68 |
| CLAYU Chavant Capital Acquisition Corp. | $10.97 | +18.34% | $27.5M | 62 |
| CLAY Chavant Capital Acquisition Corp. | $10.66 | +6.39% | $29.6M | 62 |
| INACU Indigo Acquisition Corp. | $12.08 | +16.94% | $34.9M | 60 |
| HHGC HHG Capital Corporation | $11.12 | +0.09% | $56.2M | 63 |
| MAAQ Mana Capital Acquisition Corp. | $5.99 | -24.18% | $57.0M | 61 |
| RCLFU Rosecliff Acquisition Corp I | $11.33 | +11.74% | $77.2M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are WYPH's Key Strengths?
Specialized product portfolio in niche markets.
- Proprietary diagnostic testing technology.
- Presence in over-the-counter and point-of-care markets.
- Potential for government contracts.
What Are WYPH's Weaknesses?
Limited financial resources (Market Cap: $0.00B).
- Negative P/E ratio indicating lack of profitability.
- High volatility (Beta: -8.36).
- OTC market listing increases risk.
What Could Drive WYPH Stock Higher?
Potential government contracts for explosive detection solutions.
- Increasing demand for diagnostic self-testing products.
- Development of new diagnostic tests for emerging threats.
What Are the Key Risks for WYPH?
Limited financial resources and negative profitability.
- Intense competition in the diagnostic testing market.
- Regulatory hurdles for diagnostic devices.
- OTC market listing increases risk.
- Shell company risk detected.
What Are the Growth Opportunities for WYPH?
- Expansion into Homeland Security Market: The increasing demand for security solutions presents a significant growth opportunity for WayPoint Biomedical. The market for explosive detection and biowarfare agent detection is projected to grow as global security threats evolve. Successful commercialization of its Frontline Explosive Test Kit and related products could drive revenue growth. Timeline: Ongoing.
- Increased Adoption of Diagnostic Self-Testing: The trend towards at-home diagnostic testing is growing, driven by convenience and accessibility. WayPoint Biomedical's Drink Detective and Health Essist tests could benefit from this trend. Expanding distribution channels and increasing consumer awareness could drive sales. Market Size: Expected to reach $7.7 billion by 2027. Timeline: Ongoing.
- Partnerships with Law Enforcement Agencies: Collaborating with law enforcement agencies to provide explosive detection and drug testing solutions could create a stable revenue stream. Securing contracts with government agencies and police departments could provide long-term growth opportunities. Timeline: Within the next 2-3 years.
- Development of New Diagnostic Tests: Investing in research and development to create new diagnostic tests for emerging health and security threats could drive future growth. Expanding the product portfolio to address unmet needs in the market could enhance WayPoint Biomedical's competitive position. Timeline: Ongoing.
- International Expansion: Expanding into international markets could provide access to new customers and revenue streams. Targeting countries with high security concerns or growing demand for diagnostic testing could drive growth. Conducting market research and establishing distribution networks are crucial for successful international expansion. Timeline: Within the next 3-5 years.
What Threats Does WYPH Face?
- Intense competition in the diagnostic testing market.
- Regulatory hurdles for diagnostic devices.
- Economic downturn affecting consumer spending.
- Technological obsolescence of existing products.
What Are WYPH's Competitive Advantages?
- Specialized product portfolio focusing on niche diagnostic and security applications.
- Proprietary technology in developing diagnostic tests and detection kits.
- Established presence in the over-the-counter and point-of-care markets.
- Potential for government contracts in the homeland security and defense sectors.
What Does WYPH Do?
WayPoint Biomedical Holdings, Inc. was founded in 2004 and is headquartered in Huntington Beach, California. The company operates through its subsidiary, WayPoint Biomedical, Inc., focusing on the development and marketing of diagnostic tests and devices. These products are designed for screening and monitoring human health, fitness levels, and environmental safety. A key product is the Drink Detective, a test used to detect date rape drugs such as Ketamine, GHB, and Benzodiazapines. The company also offers Health Essist tests for detecting cocaine and marijuana. Beyond health-related diagnostics, WayPoint Biomedical develops and commercializes test kits for detecting explosive devices, biowarfare/bioterrorism agents, and weapons of mass destruction. Its Frontline Explosive Test Kit is designed for detecting explosive residues. WayPoint Biomedical serves several markets, including the over-the-counter diagnostic self-testing market, the diagnostic point-of-care market, and the homeland security and defense sectors. The company's focus on specialized diagnostic solutions positions it within niche segments of the broader healthcare and security industries.
What Products and Services Does WYPH Offer?
- Develops and markets diagnostic tests for human health.
- Offers tests for detecting date rape drugs (Drink Detective).
- Provides tests for cocaine and marijuana detection (Health Essist).
- Develops test kits for detecting explosive devices.
- Creates test kits for detecting biowarfare/bioterrorism agents.
- Offers the Frontline Explosive Test Kit for explosive residue detection.
- Targets the over-the-counter diagnostic self-testing market.
- Serves the diagnostic point-of-care market.
How Does WYPH Make Money?
- Develops and manufactures diagnostic test kits and devices.
- Sells products to over-the-counter markets through retail channels.
- Markets products to point-of-care facilities such as clinics and hospitals.
- Provides solutions to homeland security and defense markets through government contracts.
What Industry Does WYPH Operate In?
WayPoint Biomedical Holdings, Inc. operates within the financial services sector as a shell company, focusing on the development and marketing of diagnostic tests and devices. The diagnostic testing market is driven by increasing health awareness and security concerns. The competitive landscape includes companies specializing in drug detection and explosive trace detection. WayPoint Biomedical's success depends on its ability to innovate and commercialize its products effectively in these competitive markets. The company's presence in the OTC market adds another layer of complexity and risk.
Who Are WYPH's Key Customers?
- Consumers seeking self-testing diagnostic solutions.
- Healthcare providers in point-of-care settings.
- Law enforcement agencies requiring drug and explosive detection tools.
- Government agencies involved in homeland security and defense.
Company Profile
WayPoint Biomedical Holdings, Inc. operates in the Specialty Business Services industry within the Industrials sector. It is headquartered in Las Vegas, US. The company is led by CEO John Richer. WYPH has traded publicly since 2015.
WayPoint Biomedical Holdings, Inc. (WYPH) Valuation Context
Relative to its peer group, WYPH's quantitative score of 47/100 is below the peer average of 63/100.
Key Financial Metrics
Return on equity for WayPoint Biomedical Holdings, Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
WYPH Financials
Bull Case vs Bear Case
Bull Case
- Specialized product portfolio in niche markets.
- Proprietary diagnostic testing technology.
- Presence in over-the-counter and point-of-care markets.
- Potential for government contracts.
Bear Case
- Limited financial resources (Market Cap: $0.00B).
- Negative P/E ratio indicating lack of profitability.
- High volatility (Beta: -8.36).
- OTC market listing increases risk.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
WYPH Latest News
No recent news available for WYPH.
WYPH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for WYPH.
Price Targets
Wall Street price target analysis for WYPH.
WYPH MoonshotScore
What does this score mean?
The MoonshotScore rates WYPH 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Shell CompaniesLeadership: Steven Fox
CEO
Steven Fox serves as the CEO of WayPoint Biomedical Holdings, Inc. Information regarding his detailed career history, education, and previous roles is not available. His background and experience in the diagnostic testing or security industries are unknown. Further research is needed to determine his qualifications and expertise.
Track Record: Due to limited information, it is difficult to assess Steven Fox's track record at WayPoint Biomedical Holdings, Inc. Key achievements, strategic decisions, and company milestones under his leadership are not readily available. The company's financial performance and market capitalization suggest significant challenges during his tenure.
WYPH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that WayPoint Biomedical Holdings, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, increasing the risk associated with investing in them. Unlike companies listed on major exchanges like NYSE or NASDAQ, OTC Other companies are not subject to the same stringent listing requirements, leading to greater potential for fraud and manipulation.
- OTC Tier: OTC Other
- Limited transparency due to unknown disclosure status.
- High risk of fraud and manipulation associated with OTC Other listings.
- Low liquidity and wide bid-ask spreads.
- Potential for delisting or trading suspension.
- Shell company risk detected.
- Verify the company's registration and legal standing.
- Attempt to obtain and review any available financial statements.
- Assess the company's business plan and revenue model.
- Research the background and experience of the company's management team.
- Evaluate the company's competitive landscape and market position.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Company has been in operation since 2004.
- Focus on developing diagnostic tests and security solutions.
- Presence in the over-the-counter and point-of-care markets.
Common Questions About WYPH (Financial Services)
What does the AI Score mean for WYPH?
WYPH holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. WayPoint Biomedical Holdings, Inc. operates in the diagnostic testing and homeland security sectors. The company develops and markets diagnostic tests and devices for health, fitness, environmental …
What does WayPoint Biomedical Holdings, Inc. do?
WayPoint Biomedical Holdings, Inc., through its subsidiary WayPoint Biomedical, Inc., develops and markets diagnostic tests and devices. These products target human health, fitness, and security applications. Key offerings include the Drink Detective for detecting date rape drugs and Health Essist tests for cocaine and marijuana detection.
What do analysts say about WYPH stock?
Analyst coverage of WYPH stock is limited due to its OTC listing and small market capitalization. Key valuation metrics such as P/E ratio (-0.25) suggest the company is not currently profitable. Growth considerations depend on successful commercialization of its diagnostic tests and expansion into the homeland security market. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks.
What are the main risks for WYPH?
The main risks for WYPH include limited financial resources, negative profitability, and high volatility. The company's OTC market listing increases the risk of fraud and manipulation. Intense competition in the diagnostic testing market and regulatory hurdles for diagnostic devices also pose challenges. The shell company risk detected further compounds the investment risk. Investors should carefully consider these factors before investing.
What regulatory challenges does WayPoint Biomedical Holdings, Inc. face?
WayPoint Biomedical Holdings, Inc. faces regulatory challenges related to the development, manufacturing, and marketing of diagnostic tests and devices. These challenges include obtaining regulatory approvals from agencies such as the FDA for its products. Compliance with quality control standards and labeling requirements is also crucial. The company's capital requirements for regulatory compliance can be significant, potentially impacting its financial performance.
How does WayPoint Biomedical Holdings, Inc. plan to address the shell company risk?
Given the shell company risk detected, WayPoint Biomedical Holdings, Inc. needs to demonstrate its commitment to transparency and operational legitimacy. This includes providing detailed financial disclosures, outlining a clear business plan, and demonstrating revenue generation from its diagnostic products. Strengthening corporate governance and engaging with investors can also help mitigate concerns. The company's ability to address this risk is crucial for attracting investor confidence.
What are the key factors to evaluate for WYPH?
WayPoint Biomedical Holdings, Inc. (WYPH) holds an AI score of 47/100 (low). presents a speculative investment opportunity given its focus on niche diagnostic testing and security solutions. Not financial advice.
How frequently does WYPH data refresh on this page?
WYPH's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven WYPH's recent stock price performance?
WayPoint Biomedical Holdings, Inc. (WYPH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product portfolio in niche markets. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO track record.
- OTC market data may be less reliable than major exchanges.
- Shell company risk detected.